MDXG MiMedx Group Inc.

MIMEDX Showcases Leading Allograft Portfolio and Its Latest Scientific and Clinical Evidence at SAWC Fall

MIMEDX Showcases Leading Allograft Portfolio and Its Latest Scientific and Clinical Evidence at SAWC Fall

Company to Sponsor Lunch Symposium and Hands-On Skills Lab

Featuring Seven Accepted Posters, Further Expanding Its Best-In-Class Portfolio of Clinical and Scientific Research  

MARIETTA, Ga., Oct. 01, 2024 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”) today announced its schedule for the Symposium on Advanced Wound Care (SAWC) Fall meeting taking place October 2-5 in Las Vegas, NV. SAWC Fall is the largest gathering of advanced wound care industry and healthcare professionals and serves as an educational forum to connect with this global community.

“Our research and clinical teams have continued to extend our leadership in expanding the understanding of placental tissue’s unique characteristics and potential clinical benefits,” said Dr. John R. Harper, Ph.D., MIMEDX Chief Scientific Officer. “At SAWC this year, we are proud to once again highlight new research on our product portfolio in two areas that are key to the wound healing cascade, namely inflammation and epithelialization. We continue striving to lead the field in scientific publications and Level I clinical data. In addition, we are excited to connect with attendees with valuable sessions, including a hands-on skills lab that will provide a deep dive into innovative treatment techniques.”   

In addition to the events highlighted below, MIMEDX sales representatives and medical science liaisons will be onsite during exhibit hall hours at booth 511 to discuss the latest product news and clinical information.

Sponsored Lunch Symposium

Wound Care Evolution: Patients Change, Practices Change, Payors Change: Providers Adapt

Date/Time: Thursday, October 3 / 11:40 a.m. – 1:10 p.m. PDT

Faculty: Ehab Sorial, MD, FACS; Naz Wahab, MD, FAAFP, FAPWCA; Dorothy Kurtz Phelan, DPM, D.BFAS, FACFAS; Allyn Forsyth, PhD

Description: This symposium will cover the rapidly changing landscape of wound care, particularly around the use and reimbursement of skin substitutes. As patient populations shift and treatment methodologies evolve, healthcare professionals must stay ahead of the curve to provide optimal care.

Hands-On Skills Lab (CME-Eligible)

Overcoming Challenges in Assessing and Managing Lower Extremity Wounds: Hands-On Workshop

Date/Time: Thursday, October 3 / 1:20 p.m. – 4:40 p.m. PDT

Moderator: Pamela Scarborough, PT, DPT, CWS, FAAWC

MIMEDX Presenter: Randall Spencer

Description: This hands-on workshop will explore innovative treatment techniques for the most common lower extremity wounds. Attendees will engage in experiential learning through product demonstrations of debridement technologies, compression therapy, negative pressure wound therapy, skin substitutes, and more.

Accepted Poster Presentations

The Company is pleased to announce that seven clinical and scientific posters have been accepted and will be on display in the poster hall. 

Clinical Research

  • Chronic Pressure Injuries: More than Taking the Pressure off with Lyophilized Human Amnion/Chorion Membrane
  • Dehydrated Human Amnion Chorion Membrane for Reconstruction of Cutaneous Defects Following Mohs Surgery: A Propensity Score-Matched Comparative Cost-Effectiveness Analysis
  • Survey of Patients with Hard-to-Heal Wounds
  • The Impacts of Medicaid Status on Venous Leg Ulcer Outcomes
  • Pyoderma Gangrenosum: A Light at the End of the Tunnel for an Orphan Disease: Dehydrated Human Amnion/Chorion Membrane

Scientific Research

  • Lyophilized Human Amnionic Membrane Modulates the Macrophage Response During Wound Healing
  • Tri-Layer Amniotic Membrane Allografts Promotes Re-Epithelialization In Vitro via cJUN Mediated Mechanism

About MIMEDX

MIMEDX is a pioneer and leader focused on helping humans heal. With more than a decade of helping clinicians manage chronic and other hard-to-heal wounds, MIMEDX is dedicated to providing a leading portfolio of products for applications in the wound care, burn, and surgical sectors of healthcare. The Company’s vision is to be the leading global provider of healing solutions through relentless innovation to restore quality of life. For additional information, please visit .

Contact:

Matt Notarianni

Investor Relations

470-304-7291



EN
01/10/2024

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on MiMedx Group Inc.

 PRESS RELEASE

MIMEDX Files Patent Infringement Lawsuit Against Surgenex

MIMEDX Files Patent Infringement Lawsuit Against Surgenex Company Set to Defend Its Extensive IP Catalog for Leading Placental Allografts MARIETTA, Ga., Dec. 17, 2024 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”) today announced that it has filed a lawsuit against Surgenex, LLC in the United States District Court for the District of Arizona. The complaint asserts that several of Surgenex’s placental allograft products infringe the Company’s patents and seeks permanent injunctive relief and monetary damages. This matter represents the second lawsuit by...

 PRESS RELEASE

MIMEDX to Participate in Upcoming Investor Conferences

MIMEDX to Participate in Upcoming Investor Conferences MARIETTA, Ga., Dec. 04, 2024 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”) today announced that members of its senior management will participate in the following investor conferences: Mizuho Health Care ConferenceWednesday, December 11, 20241:1 sessions | New York, NY Northland Growth ConferenceThursday, December 12, 20241:1 sessions | Virtual Stifel MedTech West Coast Bus TourThursday, December 12, 20241:1 sessions | Palo Alto, CA Investors interested in meeting with senior management at these...

 PRESS RELEASE

MIMEDX’s Advocacy to Rein in Runaway Medicare Spend for Skin Substitut...

MIMEDX’s Advocacy to Rein in Runaway Medicare Spend for Skin Substitutes Has Yielded Significant Results with Planned Implementation of LCDs Over 200 Unproven Skin Substitutes Will No Longer Be Covered Under Revised LCDs Company to Benefit from MACs’ Commitment to Clinically Effective, Proven Products MARIETTA, Ga., Nov. 14, 2024 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”) today provided the following update on the Local Coverage Determinations (“LCDs”) regarding “Skin Substitute Grafts/Cellular and Tissue-Based Products for the Treatment of Diabeti...

 PRESS RELEASE

MIMEDX to Participate in Upcoming Investor Conferences

MIMEDX to Participate in Upcoming Investor Conferences MARIETTA, Ga., Nov. 04, 2024 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”) today announced that members of its senior management will participate in the following investor conferences: Stifel Healthcare Conference 2024Webcast (9:45 AM ET): Monday, November 18, 2024New York, NY 15th Annual Craig-Hallum Alpha Select ConferenceTuesday, November 19, 2024New York, NY Investors interested in meeting with senior management at these events may contact their respective Stifel or Craig-Hallum representativ...

 PRESS RELEASE

MIMEDX Announces Third Quarter 2024 Operating and Financial Results

MIMEDX Announces Third Quarter 2024 Operating and Financial Results Net Sales of $84 million Grew 3% Year-Over-Year for the Third QuarterThird Quarter GAAP Net Income and Earnings Per Share were $8 Million and $0.05, RespectivelyThird Quarter Adjusted EBITDA was $18 Million, or 22% of Net SalesRaises 2024 Net Sales Growth Expectations to the High Single-DigitsManagement to Host Conference Call Today, October 30, 2024, at 4:30 PM ET MARIETTA, Ga., Oct. 30, 2024 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”), today announced operating and financial result...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch